Last reviewed · How we verify
Orasis Pharmaceuticals Ltd. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
2 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| CSF-1 | CSF-1 | phase 3 | Cytokine | CSF-1 receptor (c-FMS) | Immunology |
Therapeutic area mix
- Immunology · 3
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Amgen · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Centre for Endocrinology and Reproductive Medicine, Italy · 1 shared drug class
- King's College London · 1 shared drug class
- Radboud University Medical Center · 1 shared drug class
- Sandoz · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Orasis Pharmaceuticals Ltd.:
- Orasis Pharmaceuticals Ltd. pipeline updates — RSS
- Orasis Pharmaceuticals Ltd. pipeline updates — Atom
- Orasis Pharmaceuticals Ltd. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Orasis Pharmaceuticals Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/orasis-pharmaceuticals-ltd. Accessed 2026-06-10.